Innoviva, Inc. (INVA)
- Sector
- Pharmaceuticals
- Last price
- $20.97
- As of
Kresmion compiles this page from INVA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Innoviva, Inc. (INVA): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
See the full INVA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INVA on one page. Preview it with sample data, then open it live with a free account.
Preview the INVA dossierActive signals for INVA
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in INVA
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +492% to INVA (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 356.4%, EPS $-1.14 vs $0.4447 estimate
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +77% to INVA (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 51.0% - EPS $0.77 vs $0.51 estimate
FREE, NO ACCOUNT
Every signal on INVA, as it fires
You are seeing 5 of 10 signals recorded on INVA since 2026-05-29.
The five above landed across 4 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INVA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45781M101 · 2026Q2 | $91.7M | 0.13% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45781M101 · 2026Q2 | $57.7M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 45781MAD3 · 2026Q2 | $38.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 45781MAD3 · 2026Q2 | $25.9M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45781M101 · 2026Q2 | $23.5M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 45781M101 · 2026Q2 | $4.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 45781M101 · 2026Q2 | $3.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INVA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
INVA against its peers
INVA's operating margin of 39.8% ranks in the 97th percentile of 18 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | INVA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 411M USD | 585M USD | 45 | 20 |
| Gross margin | 74.8% | 51.4% | 79 | 6 |
| Operating margin | 39.8% | 5.6% | 97 | 18 |
| Net margin | 65.9% | 0.2% | 98 | 19 |
| Return on equity | 23.1% | -19.3% | 89 | 21 |
| P / E | 6.4x | 15.1x | 5 | 9 |
| 1 year | 25.8% | 27.4% | 46 | 24 |
Peers (25): PAHC, PCRX, OMER, OCUL, ANIP, NKTR, NUVB, GPCR, TRVI, XERS, AMPH, BHC, HRMY, LQDA, ANRO, SUPN, ALMS, ESPR, COLL, TARS, AMLX, OGN, ACRS, AVIR, AMRX. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (INVA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INVA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INVA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.